Utilization and outcomes of organs from ECMO-supported brain-dead donors: two-center experience Authors: Jihyuk Chung, Ryoung-Eun Ko, Sora Cha, Siwon Oh, Suk Kyung Lim, Jeong Hoon Yang, Kiick Sung, Min Ho Ju, Yang Hyun Cho Published: 2026 ABSTRACT BackgroundOrgan shortages remain a critical global challenge, and extracorporeal membrane oxygenation (ECMO) has emerged as a potential strategy to preserve organ perfusion and expand the donation after brain death (DBD) donor pool. In regions where donation after circulatory death (DCD) is not legally permitted, maximizing DBD donor utilization carries particular clinical and policy importance. However, evidence regarding organ-specific recovery rates and post-transplant graft outcomes in ECMO-supported DBD donors remains limited and heterogeneous.MethodsWe conducted a two-center retrospective cohort study of all consecutive brain-dead organ donors managed at two tertiary referral centers between January 2012 and June 2025. Donors were stratified by ECMO exposure prior to organ procurement. Primary outcomes were organ-specific recovery rates and the number of organs recovered per donor. Kaplan–Meier analysis with log-rank testing was used to evaluate post-transplant recipient survival stratified by donor ECMO exposure and organ type.ResultsOf 210 donors (ECMO n=25, non-ECMO n=185), baseline demographics and cause of brain death were broadly comparable, although ECMO donors more frequently had antecedent cardiac arrest (76.0% vs 53.5%, P=0.001), reflecting a population that would likely not have survived to brain death determination without extracorporeal support. Thoracic organ recovery was markedly lower in the ECMO group (heart 4.2% vs 47.6%; lung 4.2% vs 47.0%; both P<0.001), attributable primarily to underlying cardiopulmonary pathology. Abdominal organ recovery was preserved, with comparable rates for liver (75.0% vs 84.3%, P=0.586) and kidneys (right 87.5% vs 89.7%, P=0.845; left 87.5% vs 91.4%, P=0.649). Recipient survival was comparable across organ types; for liver grafts, ECMO-derived organs maintained higher survival probability at late follow-up (log-rank P=0.02), a hypothesis-generating finding that should be interpreted with caution given the small number of events.ConclusionsECMO-supported donors can preserve abdominal organ viability and achieve post-transplant recipient survival comparable to conventional DBD donors, although these findings are exploratory given the small sample size and retrospective design. Whether structured ECMO use represents a meaningful strategy for donor pool expansion, particularly in settings where DCD is unavailable, warrants confirmation in larger prospective studies.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s40560-026-00933-z. Background The persistent shortage of transplantable organs continues to limit access to life-saving transplantation [1, 2]. Extracorporeal membrane oxygenation (ECMO), initially developed as a rescue therapy for severe cardiac or respiratory failure, has recently been applied in extracorporeal cardiopulmonary resuscitation (ECPR) for refractory cardiac arrest [3]. In this context, ECMO can maintain perfusion and gas exchange, mitigate ischemic injury, and potentially expand the donor pool. With the increasing use of ECMO, particularly among patients diagnosed with brain death following cardiac arrest or brain-dead donors with cardiopulmonary dysfunction, several reports have suggested that ECMO may safely support organ preservation and thereby increase the utilization of donation after brain death (DBD). Case series, registry analyses, and single-center cohorts have demonstrated successful transplantation of organs, especially abdominal organs, procured from ECMO-supported donors [4–7]. However, findings remain heterogeneous, with variability across organ types and donor management practices, and concerns persist regarding inflammation, anticoagulation-related complications, and hemodynamic instability that may affect graft quality [8–10]. Evidence for thoracic organs is particularly limited and mixed. While ECMO can theoretically preserve heart and lung function, utilization of thoracic allografts from ECMO-supported donors has been low, and some studies have raised caution regarding post-transplant outcomes in specific settings [7, 11]. Abdominal organ utilization appears more permissive, with several studies suggesting non-inferior graft survival compared with conventional donors after appropriate selection and management [4, 6]. Many of these reports included both DBD and donation after circulatory death (DCD) donors and were conducted within heterogeneous legal and clinical systems [12, 13], limiting their generalizability to East Asian contexts. Moreover, most prior studies were small, single-center experiences with mixed donor types, leaving important knowledge gaps regarding the impact of ECMO support on DBD donor utilization and graft outcomes, particularly for thoracic organs. In regions where DBD is the sole legally authorized donation pathway and controlled DCD is not permitted, evaluating ECMO-supported DBD donors represents an important clinical and policy issue. To address these gaps, we conducted a two-center retrospective cohort study comparing DBD donors requiring ECMO support to maintain circulation with those managed conventionally. Methods Study design and population We conducted a retrospective cohort study of brain-dead organ donors managed in the intensive care units (ICUs) of two tertiary referral centers in South Korea, Samsung Medical Center (Seoul) and Pusan National University Yangsan Hospital (Yangsan), between January 2012 and June 2025. Donors were categorized into two groups based on the need for ECMO support. The ECMO group consisted of brain-dead donors who were placed on veno-arterial ECMO or veno-venous ECMO at any point during their critical care management before organ procurement. These were typically patients who had suffered cardiac arrest and were resuscitated with ECPR or who developed refractory cardiopulmonary failure while in the ICU and required ECMO to maintain organ perfusion. The control group consisted of brain-dead donors who did not require ECMO support, receiving standard care such as mechanical ventilation, continuous renal replacement therapy, and vasopressor/inotropic support as needed. In South Korea, donation after circulatory death (DCD) is not legally permitted. All organ donations in this study followed the donation after brain death (DBD) pathway. ECMO was initiated for therapeutic indications; organ donation was considered only after brain death was formally declared in accordance with national criteria. This study adhered to the ethical standards of the Declaration of Helsinki and was approved by the Institutional Review Boards of both participating centers (IRB Nos. SMC-2025-10-033-001 and PNUYH-55-2025-074); the requirement for informed consent was waived due to the observational design. As this was a purely retrospective observational study without prospective assignment of interventions, trial registration was not required. This study was reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Organ donor management Both centers operate structured extracorporeal cardiopulmonary resuscitation (ECPR) programs for out-of-hospital (OHCA) and in-hospital cardiac arrest (IHCA) patients, and have established protocols for the use of ECMO in potential brain-dead donors. Decisions to initiate ECMO in brain-dead or impending brain-dead patients with cardiopulmonary failure were made through multidisciplinary discussions involving intensivists, transplant surgeons, and organ procurement coordinators, with careful assessment of donation potential. Organ management in brain-dead donors followed standardized institutional protocols aligned with national recommendations, aiming to maintain physiologic stability and optimize organ viability. Unnecessary medications such as anticonvulsants, osmotic agents, and non-essential sedatives were discontinued upon ICU admission. Hemodynamic goals included maintaining mean arterial pressure ≥75 mmHg and systolic blood pressure ≤160–170 mmHg through fluids and vasopressors or inotropes; low-dose vasopressin was preferred in vasodilatory shock or diabetes insipidus. These hemodynamic targets reflect institutional protocol aligned with national and international donor management recommendations. The MAP target of ≥75 mmHg is consistent with the Korea Organ Donation Agency guideline (MAP 65–95 mmHg) [14] and the UNOS Donor Management Goals bundle [15]. The upper systolic blood pressure limit of ≤160–170 mmHg represents conservative institutional practice to attenuate catecholamine-driven hypertensive surges, a well-recognized hemodynamic perturbation during the sympathetic storm phase of brain death. When needed, advanced hemodynamic monitoring (e.g., pulmonary artery catheter, EV1000) guided therapy to achieve a cardiac index >2.4 L/min/m2. Mechanical ventilation used lung-protective strategies (tidal volume 6–8 mL/kg, PEEP 5–8 cmH₂O, peak inspiratory pressure ≤30 cmH₂O), with specific targets for lung donation (e.g., P/F ratio >300, FiO₂ <60%, high-dose methylprednisolone) [16]. Normothermia was maintained (36.5–37.8 °C), and core temperature kept >34 °C. Diabetes insipidus was diagnosed clinically and treated with vasopressin or desmopressin. Hormonal therapy (vasopressin, corticosteroids, thyroid hormone) was applied as indicated. Glycemic targets were 140–180 mg/dL. Infection control followed routine cultures with targeted antibiotics, and transfusion/electrolyte strategies aimed to support adequate oxygen delivery and organ perfusion. Data collection and outcomes We abstracted electronic medical records and transplant coordination databases at both centers. Key variables included donor demographics, such as age and sex, cause of brain death, ABO blood type, and detailed pre-donation characteristics, particularly the occurrence of cardiopulmonary resuscitation (CPR), type (in-hospital or out-of-hospital arrest), and the presence of bystander CPR. The time intervals from arrest to basic life support and return of spontaneous circulation were also recorded. For donors who received ECMO, additional data included the type of ECMO, the initiation context, and the transport status (whether transported with or without ECMO support). Details of organ support provided during donor management, such as intubation and renal replacement therapy, were collected. The amount and type of transfusions during ECMO, including packed red blood cells (pRBCs), platelets, fresh frozen plasma (FFP), and cryoprecipitate, were documented. Primary outcomes were organ-specific recovery proportions (heart, lung, liver, right/left kidney, pancreas, small bowel) and the number of organs recovered per donor. An exploratory outcome was recipient survival stratified by organ and donor ECMO exposure. Recipient survival was defined as the time from transplantation to death from any cause, with censoring at the date of last confirmed contact. True graft-loss events, such as return to renal replacement therapy for kidney recipients, were not systematically captured. Statistical analysis Categorical variables are expressed as number (%) with 95% confidence intervals calculated using the Wilson score method; continuous variables are expressed as mean ± standard deviation or median (interquartile range) as appropriate. Between-group differences in organ-recovery proportions were assessed using Fisher's exact test. To account for multiple comparisons across seven organ types, p values for organ-recovery proportions were adjusted using the Benjamini–Hochberg false discovery rate (FDR) procedure; FDR-adjusted p values are reported throughout. The number of organs per donor was compared using the Wilcoxon rank-sum test and was not subject to FDR correction. Kaplan–Meier estimates were used to assess recipient survival, and between-group differences were evaluated using the log-rank test. Median follow-up duration for liver graft recipients was estimated using the reverse Kaplan–Meier method. All statistical analyses were performed using R software, Version 4.1.3 (R Foundation for Statistical Computing, Vienna, Austria). Results A total of 210 donors were identified for baseline analyses (control n = 185; ECMO n = 25) (Fig. 1). Median age and sex distribution were similar between groups (46.0 [32.5–58.0] vs 45.5 [35.8–58.2] years; male 65.4% vs 60.0%) (Table 1). Causes of brain death were broadly comparable overall, although hypoxic brain injury was more frequent among ECMO donors (56.0% vs 41.6%). ABO blood type distribution did not differ significantly between groups. Pre-donation CPR was more frequent among ECMO donors (76.0% vs 53.5%, P = 0.001), with similar rates of bystander CPR and comparable time intervals from arrest to basic life support, return of spontaneous circulation, and donation.Fig. 1Study flow diagram of included organ donors. Between January 2012 and June 2025 at Samsung Medical Center and Pusan National University Yangsan Hospital, 210 brain-dead donors met eligibility for baseline analyses (non-ECMO n=185; ECMO n=25). For organ-recovery analyses, 209 donors were evaluable after excluding one ECMO donor due to inter-hospital transfer. Donors after circulatory death were not includedTable 1Baseline characteristics of donorsVariableControl group(n=185)ECMO group(n=25)PAge, years46.0 (32.5−58.0)45.5 (35.8−58.2)0.745Male sex121 (65.4)15 (60.0)0.657Cause of brain death0.190Hypoxic brain injury77 (41.6)14 (56.0)Intracranial hemorrhage53 (28.6)9 (36.0)Structural cerebrovascular disorder8 (4.3)0 (0.0)CNS pathology10 (5.4)0 (0.0)Trauma/toxic/miscellaneous30 (16.2)1 (4.0)ABO Blood type0.069A61 (33.0)11 (44.0)AB21 (11.4)6 (24.0)B51 (27.6)6 (24.0)O52 (28.1)2 (8.0)Underwent CPR before brain death99 (53.5)19 (76.0)0.001In-hospital cardiac arrest117Out-of-hospital cardiac arrest8812Bystander CPR55 (29.7)12 (48.0)0.604Time from arrest to BLS, min0.0 (0.0−5.0)0.0 (0.0−7.5)0.930Time from arrest to ROSC, min5.0 (0.0−35.0)17.5 (3.2−39.0)0.129Time from arrest to donation, days5.5 (3.2−7.0)5.5 (2.0−6.8)0.226Continuous variables are expressed as median (interquartile range), and categorical variables as number (%)ECMO extracorporeal membrane oxygenation, CNS central nervous system, CPR cardiopulmonary resuscitation, BLS basic life support, ROSC return of spontaneous circulation Study flow diagram of included organ donors. Between January 2012 and June 2025 at Samsung Medical Center and Pusan National University Yangsan Hospital, 210 brain-dead donors met eligibility for baseline analyses (non-ECMO n=185; ECMO n=25). For organ-recovery analyses, 209 donors were evaluable after excluding one ECMO donor due to inter-hospital transfer. Donors after circulatory death were not included Table 1Baseline characteristics of donorsVariableControl group(n=185)ECMO group(n=25)PAge, years46.0 (32.5−58.0)45.5 (35.8−58.2)0.745Male sex121 (65.4)15 (60.0)0.657Cause of brain death0.190Hypoxic brain injury77 (41.6)14 (56.0)Intracranial hemorrhage53 (28.6)9 (36.0)Structural cerebrovascular disorder8 (4.3)0 (0.0)CNS pathology10 (5.4)0 (0.0)Trauma/toxic/miscellaneous30 (16.2)1 (4.0)ABO Blood type0.069A61 (33.0)11 (44.0)AB21 (11.4)6 (24.0)B51 (27.6)6 (24.0)O52 (28.1)2 (8.0)Underwent CPR before brain death99 (53.5)19 (76.0)0.001In-hospital cardiac arrest117Out-of-hospital cardiac arrest8812Bystander CPR55 (29.7)12 (48.0)0.604Time from arrest to BLS, min0.0 (0.0−5.0)0.0 (0.0−7.5)0.930Time from arrest to ROSC, min5.0 (0.0−35.0)17.5 (3.2−39.0)0.129Time from arrest to donation, days5.5 (3.2−7.0)5.5 (2.0−6.8)0.226Continuous variables are expressed as median (interquartile range), and categorical variables as number (%)ECMO extracorporeal membrane oxygenation, CNS central nervous system, CPR cardiopulmonary resuscitation, BLS basic life support, ROSC return of spontaneous circulation Baseline characteristics of donors Continuous variables are expressed as median (interquartile range), and categorical variables as number (%) ECMO extracorporeal membrane oxygenation, CNS central nervous system, CPR cardiopulmonary resuscitation, BLS basic life support, ROSC return of spontaneous circulation Among ECMO donors (n = 25), VA-ECMO was used in 76.0% and VV-ECMO in 24.0% (Table 2). ECPR at initiation was documented in 68.0%. Cannulation most frequently occurred in the ICU (44.0%) or the emergency department (36.0%). Renal replacement therapy was used in 40.0% of ECMO donors. Median transfusion volumes while on ECMO were 6.0 (3.0–10.0) units of pRBCs, 3.0 (1.8–6.0) units of platelets, 2.0 (0.8–7.8) units of FFP, and 0.0 (0.0–1.0) units of cryoprecipitate. ECMO-related complications were uncommon, with cannulation-site bleeding observed in 16.0% and no recorded thrombotic, gastrointestinal, or limb ischemic events. Table 2Characteristics of donors supported with ECMOVariableN = 25ECMO type Veno-arterial*19 (76.0) Veno-venous6 (24.0) Extracorporeal cardiopulmonary resuscitation17 (68.0)Transport status Transported without ECMO support7 (28.0) Transported with ECMO support3 (12.0) Not transported15 (60.0)Cannulation location Intensive care unit11 (44.0) Emergency department9 (36.0) Catheterization lab2 (8.0) Transported3 (12.0)Organ support Intubation25 (100.0) Renal replacement therapy10 (40.0)Transfusion while on ECMO pRBCs6.0 (3.0−10.0) Platelets3.0 (1.8−6.0) FFPs2.0 (0.8−7.8) Cryoprecipitate0.0 (0.0−1.0)ECMO-related complications Thrombotic event during ECMO0 (0.0) Gastrointestinal hemorrhage0 (0.0) Cannulation site bleeding4 (16.0) Surgical site bleeding0 (0.0) Limb ischemia0 (0.0) ECMO duration, hours57.5 (17.5–142.8) SOFA score16.0 (15.0–17.0) PF ratio score4.0 (3.0–4.0) Platelet score2.0 (1.0–3.0) MAP/vasopressor score4.0 (4.0–4.0) GCS score4.0 (4.0–4.0) Bilirubin score1.0 (0.0–2.0) Creatinine score1.0 (1.0–3.0) Lactate, mmol/L9.9 (6.2–12.7)Continuous variables are expressed as median (interquartile range), and categorical variables as number (%)ECMO extracorporeal membrane oxygenation, pRBCs packed red blood cells, FFPs fresh frozen plasma, SOFA Sequential Organ Failure Assessment, PF ratio PaO₂/FiO₂ ratio, GCS Glasgow Coma Scale, MAP mean arterial pressure*One VA-ECMO donor was excluded from organ-recovery and subgroup analyses due to inter-hospital transfer (n=24 for organ-recovery analyses: 18 VA-ECMO, 6 VV-ECMO) Table 2Characteristics of donors supported with ECMOVariableN = 25ECMO type Veno-arterial*19 (76.0) Veno-venous6 (24.0) Extracorporeal cardiopulmonary resuscitation17 (68.0)Transport status Transported without ECMO support7 (28.0) Transported with ECMO support3 (12.0) Not transported15 (60.0)Cannulation location Intensive care unit11 (44.0) Emergency department9 (36.0) Catheterization lab2 (8.0) Transported3 (12.0)Organ support Intubation25 (100.0) Renal replacement therapy10 (40.0)Transfusion while on ECMO pRBCs6.0 (3.0−10.0) Platelets3.0 (1.8−6.0) FFPs2.0 (0.8−7.8) Cryoprecipitate0.0 (0.0−1.0)ECMO-related complications Thrombotic event during ECMO0 (0.0) Gastrointestinal hemorrhage0 (0.0) Cannulation site bleeding4 (16.0) Surgical site bleeding0 (0.0) Limb ischemia0 (0.0) ECMO duration, hours57.5 (17.5–142.8) SOFA score16.0 (15.0–17.0) PF ratio score4.0 (3.0–4.0) Platelet score2.0 (1.0–3.0) MAP/vasopressor score4.0 (4.0–4.0) GCS score4.0 (4.0–4.0) Bilirubin score1.0 (0.0–2.0) Creatinine score1.0 (1.0–3.0) Lactate, mmol/L9.9 (6.2–12.7)Continuous variables are expressed as median (interquartile range), and categorical variables as number (%)ECMO extracorporeal membrane oxygenation, pRBCs packed red blood cells, FFPs fresh frozen plasma, SOFA Sequential Organ Failure Assessment, PF ratio PaO₂/FiO₂ ratio, GCS Glasgow Coma Scale, MAP mean arterial pressure*One VA-ECMO donor was excluded from organ-recovery and subgroup analyses due to inter-hospital transfer (n=24 for organ-recovery analyses: 18 VA-ECMO, 6 VV-ECMO) Characteristics of donors supported with ECMO Continuous variables are expressed as median (interquartile range), and categorical variables as number (%) ECMO extracorporeal membrane oxygenation, pRBCs packed red blood cells, FFPs fresh frozen plasma, SOFA Sequential Organ Failure Assessment, PF ratio PaO₂/FiO₂ ratio, GCS Glasgow Coma Scale, MAP mean arterial pressure *One VA-ECMO donor was excluded from organ-recovery and subgroup analyses due to inter-hospital transfer (n=24 for organ-recovery analyses: 18 VA-ECMO, 6 VV-ECMO) For organ-recovery analyses, one ECMO donor was excluded due to inter-hospital transfer, leaving 24 ECMO donors for comparison (Table 3, Fig. 2). Thoracic organ recovery was markedly lower in the ECMO group: heart 4.2% vs 47.6% (P < 0.001) and lung 4.2% vs 47.0% (P < 0.001). Abdominal organ-recovery rates were similar between groups: liver 75.0% vs 84.3% (P = 0.586), right kidney 87.5% vs 89.7% (P = 0.845), and left kidney 87.5% vs 91.4% (P = 0.649). Pancreas recovery was numerically lower in ECMO donors (8.3% vs 17.8%, P = 0.649). All p values reflect Benjamini–Hochberg FDR adjustment across seven organ-type comparisons. The median number of recovered organs per donor was lower in ECMO donors compared with controls (3.0 [2.0–3.0] vs 4.0 [3.0–5.0], P < 0.001), assessed by Wilcoxon rank-sum test without FDR correction. Median ECMO support duration was 57.5 h (IQR 17.5–142.8). Despite representing a high-acuity population, with a median SOFA score of 16.0 (IQR 15.0–17.0) and peak lactate of 9.9 mmol/L (IQR 6.2–12.7), abdominal organ-recovery rates among ECMO donors were comparable to those of standard donors (Tables 2, 3). Among the 24 ECMO donors analyzed, 18 (75.0%) received VA-ECMO and 6 (25.0%) received VV-ECMO (Additional file 2). Pre-donation CPR was more frequent in the VA-ECMO subgroup (88.9% vs 33.3%, P = 0.018), consistent with the higher proportion of cardiac arrest as the precipitating event in this subgroup. Overall illness severity was similar between subgroups (SOFA score: 16.0 in both groups), and abdominal organ-recovery rates were comparable regardless of ECMO type. Due to the small size of the VV-ECMO subgroup (n = 6), these findings should be interpreted with caution. Table 3Distribution of recovered organs from donors supported with and without ECMOVariableTotal(n=209)Control group(n=185)ECMO group* (n=24)P(raw)P(FDR)Heart89 (42.6%)88 (47.6%; 40.5–54.7%)1 (4.2%; 0.7–20.2%)<0.001<0.001Lung88 (42.1%)87 (47.0%; 40.0–54.2%)1 (4.2%; 0.7–20.2%)<0.001<0.001Liver174 (83.3%)156 (84.3%; 78.4–88.9%)18 (75.0%; 55.1–88.0%)0.2510.586Kidney, right187 (89.5%)166 (89.7%; 84.5–93.3%)21 (87.5%; 69.0–95.7%)0.7240.845Kidney, left190 (90.9%)169 (91.4%; 86.4–94.6%)21 (87.5%; 69.0–95.7%)0.4640.649Pancreas35 (16.7%)33 (17.8%; 13.0–24.0%)2 (8.3%; 2.3–25.8%)0.3830.649Small bowel1 (0.5%)1 (0.5%; 0.1–3.0%)0 (0.0%; 0.0–13.8%)1.0001.000Number of organs per donor3.0 (3.0−5.0)4.0 (3.0−5.0)3.0 (2.0−3.0)<0.001NATotal column: number (%). ECMO and control columns: number (%, 95% confidence interval) for categorical variables; median (interquartile range) for continuous variables. 95% confidence intervals were calculated using the Wilson score method. p values for organ-recovery proportions were derived from Fisher's exact test and adjusted for multiple comparisons using the Benjamini–Hochberg false discovery rate (FDR) procedure; FDR-adjusted p values are presented. The number of organs per donor was compared using the Wilcoxon rank-sum test; this comparison was not included in the FDR adjustment*One ECMO patient was excluded from organ-recovery analysis due to inter-hospital transfer (n=24 for ECMO group)Fig. 2Proportions of recovered organs in ECMO vs non-ECMO donors. ECMO, extracorporeal membrane oxygenation; L, left; R, right. Bars depict recovery proportions for heart, lung, liver, right/left kidney, pancreas, and small bowel in the control (non-ECMO) and ECMO groups. Thoracic organ recovery was significantly lower with ECMO (heart 4.2% vs 47.6%, P<0.001; lung 4.2% vs 47.0%, P<0.001). Abdominal organ recovery was similar between groups (liver 75.0% vs 84.3%, P=0.586; right kidney 87.5% vs 89.7%, P=0.845; left kidney 87.5% vs 91.4%, P=0.649). Pancreas recovery was 8.3% vs 17.8% (P=0.649); small bowel 0.0% vs 0.5% (P=1.000). All p values are FDR-adjusted (Benjamini–Hochberg) Table 3Distribution of recovered organs from donors supported with and without ECMOVariableTotal(n=209)Control group(n=185)ECMO group* (n=24)P(raw)P(FDR)Heart89 (42.6%)88 (47.6%; 40.5–54.7%)1 (4.2%; 0.7–20.2%)<0.001<0.001Lung88 (42.1%)87 (47.0%; 40.0–54.2%)1 (4.2%; 0.7–20.2%)<0.001<0.001Liver174 (83.3%)156 (84.3%; 78.4–88.9%)18 (75.0%; 55.1–88.0%)0.2510.586Kidney, right187 (89.5%)166 (89.7%; 84.5–93.3%)21 (87.5%; 69.0–95.7%)0.7240.845Kidney, left190 (90.9%)169 (91.4%; 86.4–94.6%)21 (87.5%; 69.0–95.7%)0.4640.649Pancreas35 (16.7%)33 (17.8%; 13.0–24.0%)2 (8.3%; 2.3–25.8%)0.3830.649Small bowel1 (0.5%)1 (0.5%; 0.1–3.0%)0 (0.0%; 0.0–13.8%)1.0001.000Number of organs per donor3.0 (3.0−5.0)4.0 (3.0−5.0)3.0 (2.0−3.0)<0.001NATotal column: number (%). ECMO and control columns: number (%, 95% confidence interval) for categorical variables; median (interquartile range) for continuous variables. 95% confidence intervals were calculated using the Wilson score method. p values for organ-recovery proportions were derived from Fisher's exact test and adjusted for multiple comparisons using the Benjamini–Hochberg false discovery rate (FDR) procedure; FDR-adjusted p values are presented. The number of organs per donor was compared using the Wilcoxon rank-sum test; this comparison was not included in the FDR adjustment*One ECMO patient was excluded from organ-recovery analysis due to inter-hospital transfer (n=24 for ECMO group) Distribution of recovered organs from donors supported with and without ECMO Total column: number (%). ECMO and control columns: number (%, 95% confidence interval) for categorical variables; median (interquartile range) for continuous variables. 95% confidence intervals were calculated using the Wilson score method. p values for organ-recovery proportions were derived from Fisher's exact test and adjusted for multiple comparisons using the Benjamini–Hochberg false discovery rate (FDR) procedure; FDR-adjusted p values are presented. The number of organs per donor was compared using the Wilcoxon rank-sum test; this comparison was not included in the FDR adjustment *One ECMO patient was excluded from organ-recovery analysis due to inter-hospital transfer (n=24 for ECMO group) Proportions of recovered organs in ECMO vs non-ECMO donors. ECMO, extracorporeal membrane oxygenation; L, left; R, right. Bars depict recovery proportions for heart, lung, liver, right/left kidney, pancreas, and small bowel in the control (non-ECMO) and ECMO groups. Thoracic organ recovery was significantly lower with ECMO (heart 4.2% vs 47.6%, P<0.001; lung 4.2% vs 47.0%, P<0.001). Abdominal organ recovery was similar between groups (liver 75.0% vs 84.3%, P=0.586; right kidney 87.5% vs 89.7%, P=0.845; left kidney 87.5% vs 91.4%, P=0.649). Pancreas recovery was 8.3% vs 17.8% (P=0.649); small bowel 0.0% vs 0.5% (P=1.000). All p values are FDR-adjusted (Benjamini–Hochberg) Reasons for non-utilization of specific organs among ECMO donors (n = 24) are detailed in Additional file 1. The most common reasons were post-CPR myocardial dysfunction, high vasoactive-inotropic support, or acute cardiac pathology for hearts; pneumonia or positive respiratory testing for lungs; hepatitis B carrier status or liver injury for livers; and intrinsic renal disease or recipient-related issues for kidneys. Kaplan–Meier analyses demonstrated no significant between-group differences in recipient survival for right kidney (P = 0.15) or left kidney (P = 0.12). Liver recipient survival differed significantly between groups (P = 0.02) (Fig. 3). The median follow-up duration for liver graft recipients was 89.3 months (95% CI 81.4–106.0 months) in the control group and 114.6 months (95% CI 89.8 months—not reached) in the ECMO group, as estimated by the reverse Kaplan–Meier method. The single heart recipient received an organ from a 23-year-old female donor supported on VV-ECMO following brain death due to drowning. Pre-procurement echocardiography demonstrated preserved left ventricular ejection fraction (56%), and cardiac biomarkers remained within normal limits, supporting suitability for donation. The recipient survived throughout the follow-up period. The single lung recipient received an organ from a 23-year-old male donor supported on VA-ECMO following brain death due to cerebellar hemorrhage. The donor had no prior pulmonary history, with a clear chest radiograph and no evidence of infection at the time of referral. Organ procurement was performed on the day following hospital admission, minimizing the duration of mechanical ventilation and reducing the risk of ventilator-associated pulmonary complications prior to donation. The recipient survived throughout the follow-up period.Fig. 3Kaplan–Meier recipient survival by donor ECMO exposure. A Liver. B Right kidney. C Left kidney. Log-rank p values: liver 0.02, right kidney 0.15, left kidney 0.12. Heart and lung recipients (one each) are described individually in the text; Kaplan–Meier analysis was not performed for these organs owing to the single-recipient sample size Kaplan–Meier recipient survival by donor ECMO exposure. A Liver. B Right kidney. C Left kidney. Log-rank p values: liver 0.02, right kidney 0.15, left kidney 0.12. Heart and lung recipients (one each) are described individually in the text; Kaplan–Meier analysis was not performed for these organs owing to the single-recipient sample size Discussion In this two-center cohort of DBD donors, the use of ECMO at the time of brain death was associated with markedly lower thoracic organ recovery, while abdominal organ procurement and post-transplant outcomes were largely preserved. These findings align with prior reports showing that abdominal organs, particularly the liver and kidneys, remain suitable for transplantation in ECMO-supported donors, whereas thoracic organ utilization remains limited due to underlying cardiopulmonary pathology [12, 17, 18]. Importantly, recipient survival for ECMO-derived abdominal organs was comparable to that of organs recovered from standard DBD donors, with liver recipient survival curves numerically higher in the ECMO group at late follow-up, a finding requiring cautious interpretation. These observations are consistent with the hypothesis that, with appropriate donor management, ECMO may be associated with maintained systemic perfusion and organ function sufficient to support transplantation despite severe initial circulatory compromise; however, the unadjusted retrospective design precludes causal inference. A key difference between the ECMO and control cohorts was the significantly higher proportion of donors with antecedent cardiac arrest and post-resuscitation status in the ECMO group. Without extracorporeal support, these patients would likely have died before brain death determination, precluding any opportunity for organ donation. Thus, ECMO functions not only as life-sustaining therapy but also as a bridge that extends the donor pool by converting potential non-donors into viable DBD donors. This represents a clinically important population - characterized by secondary hypoxic brain injury due to circulatory failure rather than primary neurologic disease - that has traditionally been underutilized for organ donation. Globally, persistent donor shortages have prompted various strategies to expand organ donation, among which controlled DCD has played a major role. DCD has been successfully implemented in many countries, contributing significantly to increased donation rates [19, 20]. At the same time, the use of ECMO to support patients who subsequently progress to brain death represents a distinct but complementary approach to expanding the donor pool. While DCD focuses on enabling donation in the absence of brain death, ECMO-driven DBD allows preservation of organ viability in patients who are likely to progress to brain death despite maximal resuscitation efforts. Rather than competing, these two strategies can coexist within a comprehensive national donation framework, each addressing different clinical pathways and donor populations. In systems where DCD is not legally permitted, ECMO-supported DBD may provide a practical and ethically acceptable alternative for donor pool expansion; conversely, in settings with established DCD programs, ECMO-driven DBD can augment the pool by capturing additional donors who would otherwise not survive to brain death without extracorporeal support. However, the increasing use of ECPR and ECMO in cardiac arrest patients raises important ethical and social considerations. ECPR is primarily initiated with the intent of saving the patient’s life, not as a bridge to organ donation. When patients subsequently progress to brain death, this shift in purpose can create a perceived ethical collision between therapeutic and donor-focused objectives. Families often experience emotional distress and are not prepared to engage in discussions about organ donation immediately after ECPR initiation or ECMO cannulation, when hope for survival still exists. These sensitive conversations may require more time and careful communication than current clinical pathways allow. Moreover, societal debates may extend to cost allocation: questions arise as to who should bear the financial burden of prolonged ECMO support in patients who ultimately become donors-the healthcare system, organ procurement organizations, or the patient’s family. These issues highlight the need for transparent policies, ethical frameworks, and appropriate reimbursement systems to support ECMO use in this unique context. A formal health economic analysis comparing resource utilization and cost-effectiveness between ECMO-supported and conventional brain-dead donor pathways would be valuable in informing such policy decisions and represents an important direction for future research. In South Korea, where DBD remains the only legally authorized pathway for deceased donation, the importance of maximizing organ recovery from each potential donor is especially critical. ECMO is already relatively widely used, including for marginal indications, such as prolonged low-flow cardiac arrest and as a bridge to determine donation potential. In this context, the present study highlights that ECMO-supported DBD donors can contribute meaningfully to expanding the donor pool, with post-transplant outcomes comparable to conventional DBD. As countries debate the introduction of DCD, incorporating ECMO-supported DBD strategies should be considered in parallel as part of a broader, complementary framework for donor pool expansion, rather than as competing alternatives. The late divergence of liver recipient survival curves (log-rank P = 0.02) should be interpreted cautiously. Only a single graft-loss event occurred among ECMO liver recipients (1/18, 5.6%), making the Kaplan–Meier estimate statistically fragile. In addition, median follow-up differed between groups (ECMO: 114.6 months vs control: 89.3 months, reverse Kaplan–Meier), reflecting an era effect from the earlier concentration of ECMO donors, and liver grafts were accepted more selectively from ECMO donors (75.0% vs 84.3%), introducing a potential survival bias. These factors suggest the late dissociation is hypothesis-generating and warrants confirmation in larger cohorts. Future efforts should focus on optimizing thoracic organ utilization among ECMO-supported donors. In our cohort, most hearts and lungs were excluded due to primary cardiopulmonary pathology, but several cases showed potentially transplantable features that were not pursued (Additional file 1). Implementing more comprehensive cardiac and pulmonary evaluation protocols, including advanced echocardiography, biomarker assessment, and refined selection criteria, may help identify additional thoracic allografts suitable for transplantation. Concurrently, continued refinement of ECMO management protocols for potential donors, along with multidisciplinary coordination between ECMO, ICU, and transplant teams, could further improve organ quality and outcomes [21]. This study has several limitations. The sample size was relatively small, reflecting two tertiary centers over the study period, and the retrospective design introduces inherent selection bias. The comparison between ECMO-supported donors (n = 25) and non-ECMO controls (n = 185) was substantially imbalanced, as ECMO-supported brain death itself is a rare clinical event. In addition, standardized protocols for ECMO donor management are lacking, and long-term outcomes were not systematically captured. Furthermore, post-transplant outcomes were assessed as recipient survival rather than true graft survival; graft-loss events such as return to renal replacement therapy for kidney recipients were not systematically captured, which may underestimate organ-level failure rates. Finally, although VA- and VV-ECMO differ substantially in hemodynamic mechanism, patient population, and organ impact, the limited sample size precluded separate primary analyses for each modality; all main comparisons, therefore, pool both ECMO types, and this residual heterogeneity should be considered when interpreting the findings. Multicenter prospective studies with larger cohorts and standardized management guidelines are needed to strengthen the evidence base and optimize organ utilization from this challenging but valuable donor population. Conclusions This two-center retrospective study suggests that organ procurement from ECMO-supported brain-dead donors is feasible, and that transplanted organs may achieve post-transplant recipient survival comparable to that of conventional DBD donors. These findings are exploratory given the small sample size and retrospective design, and should not be interpreted as definitive evidence of equivalence. Whether ECMO support can meaningfully contribute to expanding the donor pool in settings where DCD is not permitted warrants further investigation in larger prospective studies. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 1. Supplementary Material 2.